Mayo Clinic: Amyloidosis trials

The registry lists 16 Amyloidosis studies with Mayo Clinic as lead sponsor. 3 are open to participants now and 6 have results posted.

Early Phase 1 2Phase 1 2Phase 2 8Phase 3 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
• A Study Of MCG In Cardiac AmyloidosisRecruitingNCT07218705
• A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance ElastographyRecruitingNCT07216469
• Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event MonitorsCompletedNCT04421040Not applicableResults posted
• Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisCompletedNCT01864018Phase 1/2Results posted
• Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain AmyloidosisCompletedNCT01072773Phase 2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
• CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or AmyloidosisCompletedNCT00558896Phase 2Results posted
• Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00477971Phase 3Results posted
• Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic StenosisCompletedNCT04899180Early Phase 1
• Clinical Trial to Assess the Safety of a Novel Scaffold BiomaterialActive, not recruitingNCT03584022Not applicable
• Transthyretin Cardiac Amyloidosis in HFpEFCompletedNCT03414632Early Phase 1
• Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisWithdrawnNCT03130348Phase 2
• Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve AmyloidosisCompletedNCT03019029Phase 1/2
• Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell TransplantationCompletedNCT01606280
• Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic AmyloidosisCompletedNCT00166413Phase 2